|1.||Dean, B: 2 articles (08/2009 - 03/2000)|
|2.||Huang, Xu-Feng: 2 articles (01/2007 - 09/2005)|
|3.||Zavitsanou, Katerina: 2 articles (01/2007 - 05/2005)|
|4.||Thomas, Natalie: 1 article (12/2015)|
|5.||Chen, Wei J: 1 article (12/2015)|
|6.||Lai, Chi-Yu: 1 article (12/2015)|
|7.||Scarr, Elizabeth: 1 article (12/2015)|
|8.||Dean, Brian: 1 article (12/2015)|
|9.||McLean, C: 1 article (08/2009)|
|10.||Scarr, E: 1 article (08/2009)|
|1.||Schizophrenia (Dementia Praecox)
01/30/2007 - "No difference was observed for [(3)H]AF-DX 384 binding between the schizophrenia and control groups. "
09/15/2005 - "A tendency toward decreased [(3)H]AF-DX 384 binding density (34%, P=0.09) was also observed in schizophrenia patients compared with controls. "
05/15/2005 - "Using quantitative autoradiography we measured [(3)H]AF-DX 384 binding in the anterior cingulate cortex of 15 schizophrenia, 15 bipolar, 15 major depression and 15 control cases. "
01/01/1999 - "The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia."
03/01/2000 - "Studies using tissue obtained at autopsy suggest that changes in cholinergic neurons could be important in the pathology of schizophrenia.1-4 We have previously reported a decrease in [3H]pirenzepine binding5 and [3H]AF-DX 384 binding6 to caudate-putamen (CP) from subjects who had schizophrenia. "
08/01/1995 - "In order to further evaluate this possibility, quantitative autoradiographic procedures using [3H]quinuclidinyl benzilate (for total muscarinic binding sites), [3H]pirenzepine (for muscarinic M1 sites) and [3H]AF-DX 384 (for muscarinic M2 sites) were performed at early (presymptomatic) and late (symptomatic) stages of thiamine deficiency induced in rats by administration of the central thiamine antagonist, pyrithiamine. "
|3.||Memory Disorders (Memory Loss)
08/01/1997 - "The effect of AFDX 384 on acetylcholine release and behaviour in the old rats offers further support to a relationship between the age-related cholinergic hypofunction and cognitive impairment and indicates the blockade of presynaptic muscarinic receptors as a possible selective target for therapeutic strategies aimed at improving age-associated memory deficits."
|4.||Major Depressive Disorder (Major Depressive Disorders)
|5.||Bipolar Disorder (Mania)
|2.||Muscarinic M2 Receptor
|4.||GABA-A Receptors (GABA(A) Receptor)
|7.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)